HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Thursday, 26 April 2018

NICE say “yes” to cabozatinib and “erm” to vandetanib

Cabozantinib and vandetanib for treating unresectable locally advanced or metastatic medullary thyroid cancer was recently appraised by NICE.  Sheffield was the ERG for this appraisal with Paul Tappenden, Chris Carroll, Jean Hamilton, Eva Kaltenthaler and Ruth Wong undertaking the research.

NICE were unable to release any recommendations on vandetanib and so it was split into a separate appraisal [ID1415].  This appraisal is still ongoing.

Posted by at